

Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](https://fdi-lab.sci-crunch.org) on May 6, 2025

Anti-SYNCRIP polyclonal antibody

RRID:AB_2677389

Type: Antibody

Proper Citation

(Atlas Antibodies Cat# HPA041275, RRID:AB_2677389)

Antibody Information

URL: http://antibodyregistry.org/AB_2677389

Proper Citation: (Atlas Antibodies Cat# HPA041275, RRID:AB_2677389)

Target Antigen: SYNCRIP

Host Organism: rabbit

Clonality: polyclonal

Comments: Originating manufacturer of this product. Applications: ICC-IF, IHC, WB. Orthogonal validation of protein expression using IHC by comparison to RNA-seq data of corresponding target in high and low expression tissues. Immunogen: Recombinant Protein Epitope Signature Tag (PrEST).

Antibody Name: Anti-SYNCRIP polyclonal antibody

Description: This polyclonal targets SYNCRIP

Target Organism: human

Antibody ID: AB_2677389

Vendor: Atlas Antibodies

Catalog Number: HPA041275

Record Creation Time: 20231110T034154+0000

Record Last Update: 20240725T092934+0000

Ratings and Alerts

- Antibody validation available from The Human Protein Atlas - Human Protein Atlas <https://www.proteinatlas.org/search/HPA041275>

No alerts have been found for Anti-SYNCRIP polyclonal antibody.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 3 mentions in open access literature.

Listed below are recent publications. The full list is available at [FDI Lab - SciCrunch.org](#).

Xu Y, et al. (2024) ZNF397 Deficiency Triggers TET2-Driven Lineage Plasticity and AR-Targeted Therapy Resistance in Prostate Cancer. Cancer discovery, 14(8), 1496.

Xu Y, et al. (2023) ZNF397 Loss Triggers TET2-driven Epigenetic Rewiring, Lineage Plasticity, and AR-targeted Therapy Resistance in AR-dependent Cancers. bioRxiv : the preprint server for biology.

Li X, et al. (2023) Loss of SYNCRIP unleashes APOBEC-driven mutagenesis, tumor heterogeneity, and AR-targeted therapy resistance in prostate cancer. Cancer cell, 41(8), 1427.